News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.
Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling …
Wellington Management Group LLP and its affiliates have reported a passive ownership stake of approximately 1.47% in Xenon Pharmaceuticals Inc. (XENE) common stock. This stake, representing 1,425,492 shares, is held for advisory clients across various Wellington investment entities, with no single client owning more …
Xenon Pharmaceuticals director Steven Gannon sold 10,000 Common Shares on August 11, 2026, at a weighted-average price of $64.055 per share. The shares were sold in multiple transactions ranging from $64.0517 to $64.078. Following this transaction, Gannon directly holds 1,870 Common Shares of Xenon …
H.C. Wainwright maintained a Buy rating and a $74.00 price target for Xenon Pharmaceuticals (NASDAQ: XENE), citing the FDA's lack of concerns regarding their pre-NDA meeting and the company's belief that their drug package supports approval of all four doses. The stock has seen …
HC Wainwright has revised its earnings outlook for Xenon Pharmaceuticals (NASDAQ:XENE), predicting reduced losses for Q3 2026 and subsequent fiscal years, and maintaining a "Buy" rating with a $74 price target. The biopharmaceutical company recently surpassed analyst expectations for its quarterly loss. Despite these …
Quantinno Capital Management LP significantly increased its stake in Xenon Pharmaceuticals Inc. by 125.1% in the first quarter, acquiring an additional 30,816 shares. The biopharmaceutical company, which has no product sales, reported a narrower-than-expected quarterly loss of $1.11 per share. Analyst sentiment remains largely …
Xenon Pharmaceuticals reported a net loss of US$110.74 million in Q2 2026, but its successful pre-NDA meeting with the FDA for azetukalner and a US$1.20 billion cash balance position it for potential regulatory milestones. The company is on track to submit an NDA for …
Xenon Pharmaceuticals Inc. (XENE) has seen its average 12-month price target increased by analysts to $81.21, up from $80.8, with a potential upside of approximately 26% based on its recent closing price. The consensus rating remains a "Buy" from 18 covering analysts, indicating strong …
Wedbush has increased its target price for Xenon Pharmaceuticals Inc. (XENE.O) shares to $71, up from the previous target of $63. This adjustment suggests an improved outlook from the analyst firm for the pharmaceutical company's stock. The information was released by Reuters on August …
Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business …
Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in …
Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal …
Xenon Pharmaceuticals' azetukalner NDA filing remains on track following a productive pre-NDA meeting with the FDA, according to RBC. However, the full article content is only available to premium subscribers.
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted significant progress in advancing azetukalner, with a successful pre-NDA meeting for focal seizures and a strong cash position of $1.2 billion, funding operations into 2029. The company also detailed its broad pipeline, including five additional …
Xenon Pharmaceuticals Inc. announced its Q2 2026 financial results, highlighted by the continued progress of its lead drug azetukalner, with an NDA submission for FOS on track for Q3 2026 and Phase 3 data for MDD expected in H1 2027. The company reported $1.2 …
Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily …
Xenon Pharmaceuticals is set to release its second-quarter earnings, with investors keenly watching its cash position and regulatory timeline as it approaches an FDA submission for its drug, azetukalner. Analysts anticipate a loss of $1.14 per share on $1.5 million in revenue. The company …
FMR LLC and Abigail Johnson have reported a 9.9% beneficial ownership stake in Xenon Pharmaceuticals Inc. (XENE) as of June 30, 2026. FMR LLC holds 9,599,498 common shares with sole dispositive power and sole voting power over 9,591,437 shares, while Abigail P. Johnson also …
Sei Investments Co. significantly increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 160.8% in the first quarter, now owning 114,381 shares valued at approximately $6.65 million. Other institutional investors also adjusted their holdings, contributing to institutional and hedge fund ownership of 95.45% of …
This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, indicating a favorable 36.9:1 risk-reward setup for a potential 10.9% …
This article provides a brief financial update on Xenon Pharmaceuticals Inc. (NASDAQ: XENE), focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication with no trades. The content is primarily a data point from TradingView without …
Xenon Pharmaceuticals announced equity inducement grants for eleven new non-officer employees, effective July 30, 2026. The grants include 32,758 share options with an exercise price of $64.19 per common share and 19,013 restricted share units (RSUs). These awards, approved under Nasdaq Listing Rule 5635(c)(4), …
This article from Xenon Pharmaceuticals reports on inducement grants made under Nasdaq Listing Rule 5635(c)(4). The content provided is a security check, indicating further details are likely behind this initial gate.
This article displays financial information for Xenon Pharmaceuticals Inc. (HAM:XP0), specifically its price to cash flow ratio. It notes that the market is closed and no trades have occurred for this stock. The content primarily focuses on the company's financial overview within the TradingView …
Xenon Pharmaceuticals Inc (XENE) has a current financial score of 6.41, ranking 249 out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue saw a 100% year-over-year decrease, and its net …
Xenon Pharmaceuticals Inc. announced it will report its second-quarter 2026 financial results and provide a business update on Thursday, August 6, 2026, after the close of U.S. financial markets. The company, focused on neuroscience, will host a webcast and conference call to discuss its …
Search by ticker symbol or company name and select a result to open its chart.